Alterity Therapeutics (ATHE) EBITDA (2016 - 2019)

Alterity Therapeutics has reported EBITDA for 4 years, with the latest figure at -$3.8 million in Q4 2019.

• On a quarterly basis, EBITDA fell 3.49% year-over-year to -$3.8 million in Q4 2019; TTM through Dec 2019 was -$13.0 million, a 34.24% increase from a year earlier, with the FY2026 full-year figure at -$16519.0 billion, down 115.51% from the prior year.
• EBITDA was -$3.8 million for Q4 2019 at Alterity Therapeutics, down from -$3.7 million in the prior quarter.
• The five-year high for EBITDA was -$2.7 million in Q4 2016, with the low at -$3.8 million in Q4 2019.
• Average EBITDA over 4 years is -$3.3 million, with a median of -$3.2 million recorded in 2017.
• The sharpest annual moves came in 2017 and 2018: EBITDA decreased 1.55% in 2017, then plunged 32.82% in 2018.
• Over 4 years, EBITDA stood at -$2.7 million in 2016, then declined by 1.55% to -$2.8 million in 2017, then tumbled by 32.82% to -$3.7 million in 2018, then retreated by 3.49% to -$3.8 million in 2019.
• The last three EBITDA figures came in at -$3.8 million (Q4 2019), -$3.7 million (Q4 2018), and -$2.8 million (Q4 2017), per Business Quant data.